Text Size

Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis (STRONGTREAT)

This study is currently recruiting participants.
Verified April 2013 by Centro per le Malattie Tropicali
Sponsor:
Collaborator:
European Commission
Information provided by (Responsible Party):
Centro per le Malattie Tropicali
ClinicalTrials.gov Identifier:
NCT01570504
First received: March 27, 2012
Last updated: April 3, 2013
Last verified: April 2013
History of Changes
  Purpose

Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite.

Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis.


Condition Intervention Phase
Strongyloidiasis
 Drug: Ivermectin
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis

Resource links provided by NLM:

Drug Information available for: Ivermectin
U.S. FDA Resources

Further study details as provided by Centro per le Malattie Tropicali:

Primary Outcome Measures:
  • clearance of strongyloides infection [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Clearance of infection is defined by: negative stool agar/charcoal culture - direct examination of three faecal samples for S. stercoralis AND negative serology or decrease in titer below a defined cutoff


Secondary Outcome Measures:
  • All-cause mortality during the 12 months of follow-up. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Patients with partial response to treatment at T 2 [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Patients with adverse reactions [ Time Frame: From Day 1st to Day 5th of treatment and from Day 15th to Day 19th (or 72 hours from treatment completion) ] [ Designated as safety issue: Yes ]
    grade 1 to 5 as defined in detailed protocol

  • Patients with increase in blood ALT over cutoff value [ Time Frame: Day 17 ] [ Designated as safety issue: Yes ]
  • Patients with decrease in WBC count below cutoff value [ Time Frame: Day 17 ] [ Designated as safety issue: Yes ]
  • Average difference in blood ALT and WBC count at day 17, compared with baseline [ Time Frame: Day 17 ] [ Designated as safety issue: Yes ]
  • Average difference in blood eosinophil count at T2, compared with baseline [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: March 2013
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ivermectin multiple doses
A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16
 Drug: Ivermectin
Active Comparator: 1 dose ivermectin
A single 200 mcg/kg dose of ivermectin
 Drug: Ivermectin

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients older than 5 years and weighting > 15 kg
  • Current residence in non-endemic areas
  • Either direct diagnosis of S. stercoralis infection AND positive serology at any titer OR positive serology at "high" titer, irrespective of results of direct tests

Exclusion Criteria:

  • Pregnant or lactating women
  • Subjects suffering from CNS diseases
  • Disseminated strongyloidiasis
  • Immunocompromised patients.
  • Lack of informed consent
  • Previous treatment with ivermectin (in the last year)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01570504

Contacts
Contact: Dora Buonfrate, MD +39 601 3563 dora.buonfrate@sacrocuore.it

Locations
Belgium
IMTA Not yet recruiting
Antwerp, Belgium
Italy
Centro per le Malattie Tropicali, Ospedale Sacro Cuore Recruiting
Negrar, Verona, Italy, 37024
Clinica di Malattie Infettive e Tropicali Not yet recruiting
Brescia, Italy
Unità di Malattie Infettive, Anna Meyer Children's Universisty Hospital Not yet recruiting
Florence, Italy
UFDID, Azienda Ospedaliero-universitaria Careggi Active, not recruiting
Florence, Italy
Reparto Malattie Infettive, Ospedale Ca' Foncello Not yet recruiting
Treviso, Italy
Peru
UPCH, Hospital Cayetano Heredia Not yet recruiting
Lima, Peru
Spain
Unidad de Medicina, Hospital de Poniente-El Ejido Not yet recruiting
El Ejido, Almeria, Spain
FCRB, Hospital Clinic de Barcelona Not yet recruiting
Barcelona, Spain
Unitat Medicina Tropical i Salut Internacional Drassanes Not yet recruiting
Barcelona, Spain
United Kingdom
UCLH Not yet recruiting
London, United Kingdom
Sponsors and Collaborators
Centro per le Malattie Tropicali
European Commission
  More Information

No publications provided

Responsible Party: Centro per le Malattie Tropicali
ClinicalTrials.gov Identifier: NCT01570504     History of Changes
Other Study ID Numbers: CTD1-2012, 2011-002784-24
Study First Received: March 27, 2012
Last Updated: April 3, 2013
Health Authority: Italy: Ethics Committee

Keywords provided by Centro per le Malattie Tropicali:
Strongyloidiasis
Strongyloides stercoralis
Ivermectin

Additional relevant MeSH terms:
Strongyloidiasis
Rhabditida Infections
Secernentea Infections
Nematode Infections
Helminthiasis
Parasitic Diseases
 Ivermectin
Antiparasitic Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013